Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - 14 Nov 2023 Form 4 Insider Report for CARGO Therapeutics, Inc. (CRGX)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person
Issuer symbol
CRGX
Transactions as of
14 Nov 2023
Net transactions value
$0
Form type
4
Filing time
16 Nov 2023, 16:19:24 UTC
Previous filing
19 Sep 2023
Next filing
12 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRGX Common Stock Conversion of derivative security +737,000 737,000 14 Nov 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRGX Series A-1 Preferred Stock Conversion of derivative security $0 -10,000,000 -100% $0.000000* 0 14 Nov 2023 Common Stock 737,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 13.5685-for-one basis. The Series A-1 Preferred Stock had no expiration date.